You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Title |
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
|
---|---|
Published in |
Trials, August 2021
|
DOI | 10.1186/s13063-021-05538-5 |
Pubmed ID | |
Authors |
Wendy Holman, Wayne Holman, Stacy McIntosh, Wendy Painter, George Painter, Jim Bush, Oren Cohen |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 9% |
United Kingdom | 1 | 9% |
Ukraine | 1 | 9% |
Unknown | 8 | 73% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 82% |
Science communicators (journalists, bloggers, editors) | 1 | 9% |
Scientists | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 107 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 18 | 17% |
Student > Master | 10 | 9% |
Other | 6 | 6% |
Student > Ph. D. Student | 6 | 6% |
Student > Bachelor | 6 | 6% |
Other | 14 | 13% |
Unknown | 47 | 44% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 16% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 9% |
Biochemistry, Genetics and Molecular Biology | 6 | 6% |
Immunology and Microbiology | 5 | 5% |
Agricultural and Biological Sciences | 4 | 4% |
Other | 17 | 16% |
Unknown | 48 | 45% |